PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Phase 2 Completed 21 enrolled PIQUR Therapeutics AG

NaSingle-groupOpen-labelTreatment

Summary

An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy, safety and pharmacokinetics of PQR309 in patients with relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL).

Timeline

Start: 2015-11-12
Primary completion: 2018-01-12
Completion: 2018-01-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bimiralisib	Small molecule	60 mg	Oral
Subject	Bimiralisib	Small molecule	80 mg	Oral

PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Summary

Timeline

Drugs

Indications